

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hong Kong Life Sciences and Technologies Group Limited

香港生命科學技術集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8085)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Hong Kong Life Sciences and Technologies Group Limited (the “**Company**”) is pleased to announce that Mr. Lau Ngai Cheung has been appointed as an executive Director with effect from 25 January 2019.

Mr. Lau Ngai Cheung (“**Mr. Lau**”), aged 53, has many years of experience in management and investment including construction and reclamation works and medical equipment. Mr. Lau is a director and a major shareholder of Rock-One Engineering Company Limited and Rock-One Group Life Sciences Investment Limited. Mr. Lau is the spouse of Mrs. Cheung Fan Karen (“**Mrs. Cheung**”), an executive Director, and a substantial shareholder of the Company. Mr. Lau also a business partner with Mr. Zhang James Jian Yuan, an executive Director. Mr. Lau holds a bachelor’s degree in engineering from Wahnun Industrial College, the People’s Republic of China (now known as South China University of Technology).

As at the date of this announcement, Mr. Lau is deemed to be interested in a total of 756,850,000 shares of the Company (the “**Shares**”), representing approximately 13.31% of the issued Shares, of which 4,000,000 Shares are held by Mrs. Cheung and 752,850,000 Shares are held by himself and Pacific Fortune Global Limited. Mr. Lau has a direct 100% interest in Pacific Fortune Global Limited. By virtue of the Securities and Futures Ordinance (the “**SFO**”) (Chapter 571 of the Laws of Hong Kong), Mr. Lau is deemed to be interested in 474,032,000 Shares registered in the name of Pacific Fortune Global Limited. Mr. Lau is the spouse of Mrs. Cheung, therefore, Mr. Lau is deemed to be interested in all of the Shares owned by Mrs. Cheung.

Mr. Lau has not entered into any service agreement nor has any specified or proposed length of service with the Company in respect of his appointment, but he is subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company (the “**Article**”).

Mr. Lau will be entitled to a director's fee of HK\$552,000 per annum, which has been recommended by the remuneration committee of the Company and determined by the Board with reference to his duties and responsibilities with the Company and its subsidiaries (the "Group") and the market benchmark.

Save as disclosed above, at the date of this announcement, Mr. Lau did not (i) hold any other position with the group; (ii) hold any directorships in the last three years in other listed companies; (iii) have other major appointments and professional qualifications; (iv) have any interests or underlying interests in the shares of the Company within the meaning of Part XV of the SFO; and (v) have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company (having the meaning ascribed to it the Rules (the "GEM Listing Rules") Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited).

Save as disclosed herein, there is no other matter that need to be brought to the attention of the shareholders of the Company nor other information relating to the appointment of Mr. Lau is required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

The Board would like to take this opportunity to welcome Mr. Lau to join the Company.

By order of the Board
Hong Kong Life Sciences and Technologies Group Limited
Lu Zhiqiang
Executive Director and Chief Executive Officer

Hong Kong, 25 January 2019

As at the date of this announcement, the Board comprises (i) six executive Directors, namely Mr. Lu Zhiqiang, Mr. Chui Kwong Kau, Mr. Zhang James Jian Yuan, Dr. Sun Yu, Mrs. Cheung Fan Karen and Mr. Lau Ngai Cheung; and (ii) three independent non-executive Directors, namely Mr. Hung Yat Ming, Mr. Chan Yun Hing and Mr. Tang Hua.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at <http://www.hkgem.com> for a minimum period of seven days from the date of its publication and on the Company's website at <http://www.hklifesciences.com>.